Keyphrases
Multiple Myeloma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Autologous Transplantation
100%
Newly Diagnosed multiple Myeloma
50%
High-risk Cytogenetics
50%
Median Progression-free Survival
37%
Median Overall Survival
25%
Protease Inhibitors
25%
Response Rate
25%
Immunomodulatory Drugs (IMiDs)
25%
Lenalidomide
25%
MD Anderson Cancer Center
12%
Fluorescence in Situ Hybridization
12%
Chemotherapy
12%
Patient Treatment
12%
Overall Survival
12%
Standard of Care
12%
Patient Characteristics
12%
Progression-free Survival
12%
Survival Outcomes
12%
Bortezomib
12%
Non-relapse Mortality
12%
Retrospective Analysis
12%
Patient Outcomes
12%
Single Center
12%
Second Primary Malignancy
12%
Response-outcome
12%
High-risk Disease
12%
Carfilzomib
12%
Triplet
12%
Induction Regimen
12%
Del17p
12%
Comorbidity Burden
12%
1q21 Amplification
12%
MM Patients
12%
Depth of Response
12%
1q21 Gain
12%
Medicine and Dentistry
Transplantation
100%
Multiple Myeloma
100%
Autologous Stem Cell Transplantation
100%
Progression Free Survival
50%
Overall Survival
37%
Dexamethasone
25%
Proteasome Inhibitor
25%
Lenalidomide
25%
Malignant Neoplasm
12%
Diseases
12%
Second Cancer
12%
Fluorescence in Situ Hybridization
12%
Comorbidity
12%
Patient Characteristics
12%
Non-Relapse Mortality
12%
Bortezomib
12%
Carfilzomib
12%
Immunomodulatory Drug
12%
Nursing and Health Professions
Multiple Myeloma
100%
Transplantation
100%
Autologous Stem Cell Transplantation
100%
Progression Free Survival
50%
Overall Survival
37%
Dexamethasone
25%
Lenalidomide
25%
Proteasome Inhibitor
25%
Cancer Center
12%
Second Cancer
12%
Diseases
12%
Comorbidity
12%
Health Care Quality
12%
Fluorescence in Situ Hybridization
12%
Velcade
12%
Carfilzomib
12%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
100%
Progression Free Survival
80%
Overall Survival
60%
Proteasome Inhibitor
40%
Dexamethasone
40%
Lenalidomide
40%
Diseases
20%
Malignant Neoplasm
20%
Second Cancer
20%
Chemotherapy
20%
Comorbidity
20%
Bortezomib
20%
Carfilzomib
20%
Immunology and Microbiology
Multiple Myeloma
100%
Autologous Stem Cell Transplantation
100%
Progression Free Survival
50%
Overall Survival
37%
Dexamethasone
25%
Proteasome
25%
Lenalidomide
25%
Comorbidity
12%
Fluorescence in Situ Hybridization
12%
Immunomodulatory Drug
12%
Neuroscience
Stem Cell
100%
Cytogenetics
50%
Dexamethasone
25%
Proteasome Inhibitor
25%
Lenalidomide
25%
In Situ Hybridization
12%
Bortezomib
12%
Comorbidity
12%
Carfilzomib
12%